Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer
Published Date: April 16, 2025
Neratinib, a tyrosine kinase inhibitor, offers a significant option for extending adjuvant treatment in patients with early-stage HER2-positive breast cancer following trastuzumab therapy.
In this short video, Dr. Adam Brufsky, MD, PhD, FACP, Professor of Medicine at the University of Pittsburgh, and Co-Director of the Comprehensive Breast Cancer Center at the UPMC Hillman Cancer Center, provides essential insights on integrating neratinib into treatment plans.
Video Overview:
-
Dr. Brufsky discusses neratinib’s role in reducing recurrence risk and improving invasive disease-free survival.
-
The video offers practical strategies for managing neratinib-induced diarrhea, emphasizing dose escalation and prophylaxis.
-
Learn about the NCODA PQI and Treatment Support Kit, which provide healthcare professionals with the tools needed to manage side effects and support patient adherence.
Sponsored by
